» Articles » PMID: 37367731

Bittersweet Sugars: How Unusual Glycan Structures May Connect Epithelial-to-Mesenchymal Transition and Multidrug Resistance in Cancer

Abstract

Cancer cells are characterized by metabolic reprogramming, which enables their survival in of-ten inhospitable conditions. A very well-documented example that has gained attraction in re-cent years and is already considered a hallmark of transformed cells is the reprogramming of carbohydrate metabolism. Such a feature, in association with the differential expression of en-zymes involved in the biosynthesis of glycoconjugates, generically known as glycosyltransfer-ases, contributes to the expression of structurally atypical glycans when compared to those ex-pressed in healthy tissues. The latest studies have demonstrated that glycophenotypic alterations are capable of modulating multifactorial events essential for the development and/or progres-sion of the disease. Herein, we will address the importance of glycobiology in modern medi-cine, focusing on the ability of unusual/truncated -linked glycans to modulate two complex and essential phenomena for cancer progression: the acquisition of the multidrug resistance (MDR) phenotype and the activation of molecular pathways associated with the epithelial-mesenchymal transition (EMT) process, an event deeply linked with cancer metastasis.

Citing Articles

Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy.

Mengistu B, Tsegaw T, Demessie Y, Getnet K, Bitew A, Kinde M Cancer Cell Int. 2024; 24(1):406.

PMID: 39695669 PMC: 11657890. DOI: 10.1186/s12935-024-03558-0.

References
1.
Taniguchi N, Ihara S, Saito T, Miyoshi E, Ikeda Y, Honke K . Implication of GnT-V in cancer metastasis: a glycomic approach for identification of a target protein and its unique function as an angiogenic cofactor. Glycoconj J. 2003; 18(11-12):859-65. DOI: 10.1023/a:1022292223878. View

2.
Dos Reis J, da Costa Santos M, Da Costa K, Geraldo Freire-de-Lima C, Morrot A, Previato J . Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells. Matrix Biol. 2023; 118:47-68. DOI: 10.1016/j.matbio.2023.03.002. View

3.
Nakagawa Y, Nakayama H, Nagata M, Yoshida R, Kawahara K, Hirosue A . Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. Int J Oncol. 2014; 44(4):1376-84. DOI: 10.3892/ijo.2014.2265. View

4.
Fonseca L, da Silva V, Freire-de-Lima L, Previato J, Mendonca-Previato L, Capella M . Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?. Front Oncol. 2016; 6:158. PMC: 4916178. DOI: 10.3389/fonc.2016.00158. View

5.
Matsuura H, Greene T, Hakomori S . An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J Biol Chem. 1989; 264(18):10472-6. View